Vimian Group acquires veterinary orthopedic implants business in the US

News
Aug 04 2022

Vimian Group acquires veterinary orthopedic implants business in the US

Vimian Group has acquired the assets of New Generation Devices (NGD), a veterinary orthopedic implants company in New Jersey, US. The acquired business has annual revenues of around USD 4.5 million.

Vimian’s MedTech segment Movora has acquired the assets of New Generation Devices (NGD). Founded in 2001, NGD offers a selected range of veterinary orthopedic implants to veterinary clinics across the United States with focus on implants for ruptured cruciate ligaments (TPLO) and fracture plates. As part of the transaction, Movora has also acquired an exclusive license in the veterinary field that gives access to Citrate-BP, a synthetic biomaterial to guide tissue regeneration.

“Through this acquisition we gain access to a new loyal customer base to which we can offer our full product portfolio of veterinary orthopedic implants and surgical instrumentation. We also gain the global license to a new, innovative technology in the veterinary market. This acquisition has a clear strategic fit with Movora and significant synergy potential, says Chris Sidebotham, Co-CEO of Vimian’s MedTech segment Movora.

The acquisition will have a marginal impact on Vimian Group's earnings per share in the current financial year. The acquisition was consolidated into Vimian Group’s MedTech segment on 1 August.

About Vimian

Vimian is a global, fast-growing group of innovation-driven companies with a shared passion for making a positive impact through improving animal health. Together, we put science, technology and our customers’ needs at the centre of everything we do to deliver effective solutions to veterinary professionals, labs and pet parents around the world. We bring together pioneering and entrepreneurial businesses in animal health, with an aim to create a uniquely diversified proposition of products and services of the highest standard. Our group covers four essential and rapidly evolving areas within animal health: Specialty Pharma, Diagnostics, Veterinary Services and MedTech. Vimian provides individual businesses with access to our networks, expertise, infrastructure and capital to accelerate innovation and growth. We are as passionate about supporting leadership within our existing businesses, as we are about welcoming new partners to the Vimian family – together helping us make an even greater impact by improving animal health. Headquartered in Stockholm, Sweden, Vimian and our family of companies reach over 15,000 customers in +150 markets, employ more than 700 people and have a combined annual turnover of approximately EUR 170 million. FNCA Sweden AB is appointed the Company’s Certified Adviser, info@fnca.se, +46 (0) 8-528 00 399. For more information, please visit: www.vimian.com.